Qilu Pharmaceutical's Class 1 New Drug QLS5132 Injection Receives IND Approval for Combination Therapy in Advanced Solid Tumors

Stock trading depends onGolden Qilin Analyst Report, authoritative, professional, timely, comprehensive, help you explore potential thematic opportunities!

(Source: Cailian Press)

At the 2025 American Association for Cancer Research (AACR) Annual Meeting, preclinical data disclosed by Qilu Pharmaceutical showed that QLS5132 demonstrated potent antitumor activity in animal models. It achieved durable responses even in models resistant to existing ADC drugs while exhibiting good safety. In addition, the latest clinical research progress of QLS5132 will be presented as an oral report at the upcoming 2026 AACR Annual Meeting in April.

This year, Qilu Pharmaceutical has maintained a strong momentum of innovation, with five innovative drugs being approved for clinical trials for the first time. Additionally, new indications for several other innovative drugs have been approved for clinical trials, including cutting-edge technology platforms such as ADC, small molecule targeted therapy, monoclonal antibodies, and small nucleic acids. In recent years, Qilu Pharmaceutical's innovation pipeline has been rapidly transitioning from "single-point breakthroughs" to a "comprehensive layout," establishing a differentiated product portfolio covering major unmet therapeutic areas such as oncology, immunology, metabolism, cardiovascular, and central nervous system diseases.

In the future, Qilu Pharmaceutical will fully advance the clinical research of QLS5132, striving to bring new hope and better treatment options to patients as soon as possible. Adhering to the mission of "expressing our love through technology," the company will continue to develop more "global new" and "globally excellent" drugs.